Group One Trading, L.P. Biomarin Pharmaceutical Inc Transaction History

Group One Trading, L.P.

$2.2 Billion
Q1 2025

A detailed history of Group One Trading, L.P. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Group One Trading, L.P. holds 103,957 shares of BMRN stock, worth $6.31 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

103,957

Previous 126,622 17.9%

Holding current value

$6.31 Million

Previous $8.32 Million 11.7%

% of portfolio

0.33%

Previous 0.31%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$61.25 - $72.83 $1.39 Million - $1.65 Million	-22,665 Reduced 17.9%	103,957 $7.35 Million
Q4 2024 Feb 14, 2025	BUY	$61.93 - $70.49 $4.24 Million - $4.83 Million	68,474 Added 117.76%	126,622 $8.32 Million
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $1.56 Million - $2.12 Million	22,576 Added 63.47%	58,148 $4.09 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $1.14 Million - $1.41 Million	15,329 Added 75.72%	35,572 $2.93 Million
Q1 2024 May 10, 2024	BUY	$83.81 - $99.0 $1.7 Million - $2 Million	20,243 New	20,243 $1.77 Million
Q3 2023 Nov 09, 2023	SELL	$85.07 - $94.48 $4.27 Million - $4.74 Million	-50,188 Reduced 86.14%	8,073 $714,000
Q2 2023 Aug 09, 2023	BUY	$86.68 - $100.3 $5.05 Million - $5.84 Million	58,261 New	58,261 $5.05 Million
Q4 2022 Feb 09, 2023	SELL	$80.93 - $108.63 $1.74 Million - $2.34 Million	-21,547 Reduced 55.38%	17,361 $1.8 Million
Q3 2022 Nov 09, 2022	SELL	$82.16 - $96.94 $1.96 Million - $2.32 Million	-23,889 Reduced 38.04%	38,908 $3.3 Million
Q2 2022 Aug 11, 2022	BUY	$71.48 - $86.85 $1.49 Million - $1.81 Million	20,814 Added 49.58%	62,797 $5.2 Million
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $839,289 - $1.05 Million	-11,299 Reduced 21.21%	41,983 $3.24 Million
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $686,934 - $876,099	9,578 Added 21.92%	53,282 $4.71 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $566,906 - $648,033	-7,582 Reduced 14.78%	43,704 $3.38 Million
Q2 2021 Aug 10, 2021	SELL	$75.51 - $84.79 $2.73 Million - $3.06 Million	-36,145 Reduced 41.34%	51,286 $4.28 Million
Q1 2021 May 12, 2021	SELL	$74.73 - $90.69 $4.1 Million - $4.97 Million	-54,827 Reduced 38.54%	87,431 $6.6 Million
Q4 2020 Feb 10, 2021	BUY	$72.61 - $90.2 $4.33 Million - $5.38 Million	59,676 Added 72.26%	142,258 $12.5 Million
Q3 2020 Nov 12, 2020	BUY	$71.87 - $131.03 $5.94 Million - $10.8 Million	82,582 New	82,582 $6.28 Million
Q1 2020 May 13, 2020	SELL	$71.37 - $96.85 $626,914 - $850,730	-8,784 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$64.27 - $86.37 $3.81 Million - $5.11 Million	-59,210 Reduced 87.08%	8,784 $743,000
Q3 2019 Nov 12, 2019	BUY	$67.4 - $85.11 $3.92 Million - $4.95 Million	58,146 Added 590.43%	67,994 $4.58 Million
Q2 2019 Aug 09, 2019	BUY	$80.35 - $93.9 $791,286 - $924,727	9,848 New	9,848 $843,000
Q1 2019 May 13, 2019	SELL	$84.2 - $98.62 $2.85 Million - $3.34 Million	-33,858 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$80.14 - $106.07 $267,106 - $353,531	-3,333 Reduced 8.96%	33,858 $2.88 Million
Q3 2018 Nov 08, 2018	BUY	$93.92 - $105.72 $770,801 - $867,644	8,207 Added 28.32%	37,191 $3.61 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $880,499 - $1.15 Million	11,584 Added 66.57%	28,984 $2.73 Million
Q1 2018 May 11, 2018	SELL	$77.67 - $92.63 $7.76 Million - $9.25 Million	-99,877 Reduced 85.16%	17,400 $1.41 Million
Q4 2017 Feb 09, 2018	BUY	$80.76 - $95.13 $8.21 Million - $9.68 Million	101,704 Added 653.08%	117,277 $10.5 Million
Q3 2017 Nov 15, 2017	BUY	$80.6 - $94.95 $1.04 Million - $1.22 Million	12,890 Added 480.43%	15,573 $1.45 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,683	2,683 $244,000

Others Institutions Holding BMRN

# of Institutions

667

Shares Held

186M

Call Options Held

1.25M

Put Options Held

992K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Biomarin Pharmaceutical Inc Transaction History